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Abstract
Uncertainty about the incidence and prevalence of amyotrophic lateral sclerosis (ALS), as well as 
the role of the environment in the etiology of ALS, supports the need for a surveillance system/
registry for this disease. Our aim was to evaluate the feasibility of using existing administrative 
data to identify cases of ALS. The Agency for Toxic Substances and Disease Registry (ATSDR) 
funded four pilot projects at tertiary care facilities for ALS, HMOs, and state based organizations. 
Data from Medicare, Medicaid, the Veterans Health Administration, and Veterans Benefits 
Administration were matched to data available from site-specific administrative and clinical 
databases for a five-year time-period (1 January 2001–31 December 2005). Review of information 
in the medical records by a neurologist was considered the gold standard for determining an ALS 
case. We developed an algorithm using variables from the administrative data that identified true 
cases of ALS (verified by a neurologist). Individuals could be categorized into ALS, possible 
ALS, and not ALS. The best algorithm had sensitivity of 87% and specificity of 85%. We 
concluded that administrative data can be used to develop a surveillance system/ registry for ALS. 
These methods can be explored for creating surveillance systems for other neurodegenerative 
diseases.
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Introduction
Although amyotrophic lateral sclerosis (ALS) (1) was first described by the French 
neurologist Jean-Martin Charcot in 1896, there is still little known about its causes.
Reports from the United States and other countries indicate an annual incidence rate of 0.2 
to 2.4 per 100,000 population and a prevalence of 0.8 to 7.3 per 100,000 population (2). The 
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onset of ALS is age related with the highest rate of onset occurring between 55 and 75 years 
of age (2–4). The average survival time after onset of symptoms is approximately three 
years, and only a small proportion of patients survive beyond five years (2). ALS is more 
common in males than females by a ratio of 1.5–2:1 (4,5), but recent studies have suggested 
that this difference is decreasing (4,6).
Uncertainty about the incidence and prevalence of ALS, as well as the role of the 
environment in the etiology of ALS, supports the need for a surveillance system for this 
disease (7,8). In addition, such a system could provide an unbiased source from which to 
recruit patients to participate in research studies.
For more than 15 years, researchers have understood the importance of clinical databases in 
the study of ALS. A number of registries were initiated across Europe including but not 
limited to registries in Scotland (9,10), Ireland (11), Piemonte and Valle d’Aosta, Italy (12), 
and Sclerosi Laterale Amiotrofica – Puglia (SLAP) (13). In order to recruit a large 
population based sample of patients with ALS and to collect baseline information on newly 
diagnosed patients across Europe, the EURALS registry was established by merging 
information collected from existing national and regional registries in Italy, Ireland, 
England, and Scotland and collecting information on newly diagnosed patients in other 
countries such as Spain and Serbia where population based registries were no longer 
available (14). Differences in ethnic diversity, population size, and healthcare delivery 
model between European countries and the United States, make the methods used to develop 
the European registries less likely to be able to be implemented in the Unites States.
There have only been two attempts to create large databases of ALS patients in the United 
States. The first large such database was the ALS Patient Care Database with the primary 
purpose of improving the quality of care for patients with ALS. This observation database 
was begun in 1996 and was available to all neurologists practicing in North America (15).
The only other registry of ALS patients in the United States is the national registry of 
Veterans with ALS (16). Neither of these registries is enrolling any new participants.
A bill to amend the Public Health Service Act to provide for the establishment of an 
Amyotrophic Lateral Sclerosis Registry, S. 1382: ALS Registry Act, was signed into law on 
10 October 2008 by President Bush and became Public Law No: 110-373. Given the issues 
of implementing methodologies developed in Europe and that the authority to make a 
disease reportable in the United States rests with the states which historically have reserved 
this designation for infectious diseases, the Agency for Toxic Substances and Disease 
Registry (ATSDR) decided to determine the feasibility of using administrative data to 
populate such a registry.
Methods
To evaluate the feasibility of using existing administrative data to identify cases of ALS, 
ATSDR funded four diverse pilot projects to be conducted by the Mayo Clinic (Rochester 
and Olmsted County, Minnesota), Emory University, the South Carolina Policy Board, and 
nine members of the HMO Research Network (HMORN) in California, Oregon, 
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Pennsylvania, Wisconsin, New Mexico, Michigan, and Massachusetts. The Mayo Clinic and 
Emory University were tertiary care facilities with neurologists who specialized in the 
diagnosis and treatment of persons with ALS; however, only cases of ALS in the defined 
catchment areas were included. The Mayo Clinic also had access to information about 
individual healthcare utilization for all residents of Rochester and Olmsted County. The 
South Carolina Policy Board had access to more than 18 databases covering individual 
health care utilization and spending for residents of the entire state. The members of the 
HMORN covered a large racially and ethnically diverse population throughout the country 
from both urban and rural areas.
Each of these four pilot projects matched data from Medicare, Medicaid, the Veterans 
Health Administration (VHA), and the Veterans Benefits Administration (VBA) to data 
from site-specific administrative and clinical databases (e.g. ALS clinic records) for a five-
year time- period (1 January 2001–31 December 2005). The national databases covered 
approximately 90 million people. VHA data include inpatient, outpatient, and pharmacy 
records for veterans receiving healthcare benefits. Approximately 20% of veterans qualify 
for this benefit. VBA data include records for veterans receiving pensions or compensation 
for disabilities considered service related. During the study period, ALS was considered 
service related if it was diagnosed within one year of separation from active duty. Medicare 
data included inpatient and outpatient records. Medicare is United States government-
provided insurance for people aged 65 years or older, some disabled people under age 65 
years, and people of all ages with End-Stage Renal Disease. Individuals approved for the 
Social Security Administration Disability Insurance Benefit or Supplemental Security 
Income because of ALS can begin receiving Medicare without a 24-month waiting period. 
Medicaid data include inpatient, outpatient, and pharmacy records for individuals receiving 
this benefit. Medicaid is the United States health program for individuals and families with 
low incomes and resources.
From the national databases, ATSDR identified individual patient encounters resulting in an 
ICD-9 code for any MND (335.2–335.29) and VBA-specific codes for any MND for the 
specific project catchment area (Table I). ATSDR then provided individual encounter data 
including full name and social security number to the pilot projects. Many of the data sets 
contained up to 10 ICD-9 codes for an encounter. The MND code could be in any position, 
not just the primary diagnosis.
For the Mayo Clinic and the state of South Carolina, catchment area was easily defined by 
county or state boundaries. However, defining catchment areas for Emory and the HMORN 
sites was more difficult because not everyone in a defined geographic area used the specific 
institution/provider services. Catchment area for each site was determined based on the site 
investigator’s knowledge of penetration into the surrounding counties. Zip codes, which 
change over time, could not be used.
To identify additional potential cases of ALS, sites evaluated administrative and clinical 
databases available to them.
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Pilot sites completed a standardized spreadsheet for each individual found in any available 
database. Individuals could have multiple records for a single encounter in the databases, 
e.g. physician and neuroimaging, and multiple encounters. All encounter records from all 
databases were combined into one record per individual. The spreadsheet included the years 
in which an individual had records, in which database(s) a record was found, ICD-9 code 
recorded for the encounter (ALS or other MND), prescription for riluzole, and types of 
providers seen (e.g. neurologist, internal medicine). Using a standardized medical records 
abstraction form designed by the project neurologists, accessible medical records were 
abstracted for signs and symptoms of ALS and EMG results when available and diagnoses 
were verified by a neurologist using the El Escorial criteria (17), which was considered the 
‘gold standard’. Those records that did not have enough information to make the 
determination were classified as possible ALS to be evaluated as additional data become 
available. A de-identified dataset was sent to ATSDR. That dataset included the spreadsheet 
information for all individuals who were identified in any of the databases with an ICD-9 
code for any MND or VBA-specific code for any MND, and who had their medical record 
reviewed by a neurologist regardless of the neurologist’s determination. ATSDR combined 
the data from the four pilot projects for this analysis.
A more detailed description of the methodology used and findings of the pilot projects 
conducted by the South Carolina Budget Control Board (18) and Emory University (19) can 
be found in the site-specific publications.
ATSDR determined that these pilot projects were not human subjects research.
Results
Approximately 24,000 individuals were identified with an MND ICD-9 code in the national 
and local databases. The pilot projects reviewed approximately 4700 local medical records 
(Table II). Except at the HMORN sites, most of the charts reviewed were for individuals 
identified through the national databases. The percentage of charts with MND codes 
identified only through site review ranged from 1% (Mayo Clinic) to 77% (HMORN). Table 
III shows the demographic characteristics of all the individuals identified with an ICD-9 
code or VBA-specific code for any MND and those individuals for whom charts were 
reviewed. There was a significant difference in the racial, gender and age distribution of 
those whose charts were reviewed, i.e. a greater percentage of the medical records of blacks 
and unknown race, males, and younger cases was reviewed.
Table IV examines the demographic characteristics of those with an ALS ICD-9 code 
(335.20) and those with any other MND ICD-9 code (335.2, 335.21–335.24, and 335.29) for 
whom medical records were reviewed. Consistent with what we know about the 
demographics of ALS patients, those with an ALS code were more likely to be white, male, 
and between the ages of 40 and 79 years.
The sensitivity and specificity of individual variables and combined variables were 
evaluated. For example, having the ALS code in at least one encounter had a sensitivity of 
96% and specificity of 52%. Using our knowledge of ALS and findings from other 
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algorithm building studies, variables were combined into the algorithm to maximize both 
sensitivity and specificity. It was possible to develop an algorithm using variables from the 
administrative data that identified true cases of ALS (as verified by a neurologist) (Table V). 
Individuals were placed into one of three categories: ALS, Possible ALS, and Not ALS. Any 
individual not falling into the ALS or Not ALS category was in the possible ALS category 
(not shown). For example, an ALS code in two years but no visit to a neurologist would be 
in the possible ALS category and re-evaluated as new data become available. The best 
algorithm had sensitivity of 87% and specificity of 85%.
Discussion
Increasingly, electronically available data collected for purposes other than research, such as 
claims data, are being used in epidemiological studies. A great deal of research has gone into 
the reliability for research purposes of coding in large datasets such as Medicare and 
Medicaid because the information was collected for other uses such as claims. Most of the 
research has focused on identifying a specific disease or procedure using codes and 
comparing that with the medical record, which is considered the gold standard (20–23). One 
study comparing the accuracy of Medicare hospital claims with the hospital records found 
that for Diseases of the Nervous System and Sense Organs (ICD-9-CM: 320–389), the 
agreement between the coding and the medical record was 91.4% (24).
Causes for an erroneous code in a claims database can range from computer entry errors to 
lack of sufficient clinical information to accurately code the claim (25). Changes in 
reimbursement based on Diagnosis Related Group (DRG) may also cause some coding 
inconsistencies.
Many studies use only one database. Researchers must understand the limitations of the data 
being used (26) and evaluate the database on a macro level to assess gaps (27). Several 
researchers have pointed out that obtaining accurate information relies on review of multiple 
encounters/reports because diagnoses can change (28) and chronic conditions may not be 
listed in each encounter (29). In a review of strengths and limitations of Medicaid data for 
epidemiologic research the authors point out that it may be hard to identify incident 
conditions (33). The first mention of a condition does not necessarily indicate that it was 
diagnosed on that date but might merely indicate the first time it was documented. Requiring 
documentation of additional procedures along with the diagnosis can assist in identifying 
incident cases (31). In a study of hip fracture, investigators developed an algorithm that 
defined hip fractures using both diagnosis and procedure codes and a combination of 
information from both hospital claims and Part B claims (outpatient) for Medicare 
recipients. Even for a condition that is almost certainly treated on an inpatient basis, some 
claims would have been missed without the outpatient information. The authors of this study 
also point out the importance of including information from the Veterans Administration 
(VA) because some Medicare recipients might receive care at a VA facility, information 
which would not be reflected in the Medicare files (32). Therefore, using multiple data sets, 
creating an algorithm to identify cases that include inpatient and outpatient information, as 
well as using a combination of diagnoses and procedures, can also increase the certainty of 
the diagnosis.
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In addition, it is important in chronic diseases to look at multiple years of data. In a study by 
Pope et al., the prevalence of MS increased with the length of observation. The prevalence 
estimate for one year of claims for the privately insured population was 18 per 10,000 
enrollees, 29 per 10,000 Medicare enrollees, and 53 per 10,000 Medicaid disabled enrollees. 
When two years of data were used to determine who had MS, the prevalence estimated 
increased to 24, 36 and 71 per 10,000 enrollees, respectively (33). In another study 
examining the accuracy of Medicare claims data for identifying Alzheimer’s disease, the 
authors determined that a minimum of three years of data were needed to identify the 
patients. More years of data increased the number identified, but only slightly. In addition, 
hospital files alone identified only 29% of the patients, whereas physician encounters and 
institutional outpatient files together identified 75% of the patients. Using five years of 
inpatient and outpatient data, researchers identified 79% of the cases. An analysis of clinical 
data on the patients revealed that those with less severe disease were less likely to be 
identified (34).
Our experience using administrative data for the identification of true ALS cases is similar 
to that found by others. Using multiple years of data to ensure that the individual had a 
definitive diagnosis of ALS rather than as one possible diagnosis, increased the sensitivity 
and positive predictive value (data not shown). Linking patient’s data in data sets from 
different sources (e.g. being able to link physician encounter data in Medicare with 
prescription data from the Veterans Health Administration) strengthened the ability to 
identify true cases. Similar results were found when data from the individual pilot projects 
were analyzed.
Many of the data sets contained up to 10 ICD-9 codes for an encounter. It was important to 
consider all these codes and not just the primary diagnosis because ALS might not be the 
reason for the visit to a medical provider. For example, an individual might be seen in the 
emergency room for difficulty breathing, which was listed as the primary diagnosis for the 
visit; however, difficulty breathing was secondary to ALS, which was listed among the other 
codes. There were concerns that individuals with ALS would have one of the other MND 
codes in their administrative records and that cases of ALS would be missed. However, we 
found that MND codes other than the specific code for ALS were often misused, particularly 
the codes for Progressive Muscular Atrophy and Pseudo Bulbar Palsy. For example, these 
codes were often used to describe symptoms attributable to other conditions such as 
Parkinson’s disease, stroke, and post-polio syndrome. Data from Table IV support this 
finding, which shows a larger percentage of individuals 80+ years of age with an MND code 
other than ALS. The highest onset of ALS is between 55 and 75 years of age (2–4). 
Therefore, individuals whose administrative records included only MND codes for 
conditions other than ALS and never included the ALS specific code of 335.20 were 
considered definitely not to have ALS.
Within the HMOs, the number of charts reviewed compared with the number of records 
identified was small. This number is misleading because the national data could be 
identified only to the county level. The HMOs defined their catchment areas based on 
county, realizing it was not completely accurate and not everyone in a county was a member 
of their HMO. Therefore, we believe that the percent of possible individuals with ALS who 
KAYE et al. Page 6













belonged to the HMO and for whom a chart was reviewed was much larger. In addition, the 
number of cases found only in the HMO databases was higher than those found in the site-
specific databases of the other sites. This could be because the Medicare data are encounter 
data and do not include Medicare recipients who choose the HMO option. This is a 
limitation of Medicare data for identifying cases of specific diseases.
Conclusion
There is a public health need for accurate estimates of people affected by neurodegenerative 
diseases to better assess the healthcare needs of the population, detect changes in healthcare 
practices, and assess the burden of disease. Although the idea of a comprehensive public 
health surveillance system using existing data was described more than 10 years ago (35), 
there have been no attempts to initiate such a system on a national level.
Our results suggest that administrative data can be used to create an ALS surveillance 
system although it will be necessary to identify other sources of data to capture those ALS 
cases not covered by the administrative databases. Although these databases do not cover 
the entire population of the U.S., they represent a significant portion of the population most 
likely affected by ALS because Medicare covers individuals 65 years of age or older and 
those with certain diseases such as ALS. Not all ALS patients will apply for benefits; 
however, while only 13% of Medicare beneficiaries overall are less than 65 years of age, our 
data show a significant number of ALS patients (41%) identified in Medicare are less than 
65 years of age. Since completion of the pilot project, Medicare Part D (prescription 
coverage) is now offered and the addition of these new data will be evaluated to determine 
how to use them in further refining the algorithm to optimize sensitivity and specificity. In 
addition, the six validation questions used by the VA to screen individuals for the VA ALS 
registry were found to be very accurate (93.4% of those who passed the screening questions 
were determined by a neurologist to have ALS) (36) and could be used to allow ALS 
patients to self-identify. These methods can be explored for creating surveillance systems for 
other neurodegenerative diseases.
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Table I
Motor neuron disease codes (ICD-9-CM, ICD-10 and VBA) used to identify potential ALS cases.
System Code Description
ICD-9-CM 335.2 Motor neuron disease unspecified
ICD-9-CM 335.20 Amyotrophic lateral sclerosis
ICD-9-CM 335.21 Progressive muscular atrophy
ICD-9-CM 335.22 Progressive bulbar palsy
ICD-9-CM 335.23 Pseudobulbar palsy
ICD-9-CM 335.24 Primary lateral sclerosis
ICD-9-CM 335.29 Other motor neuron disease
ICD-10 G12.2 Motor neuron disease
VBA 8017 Amyotrophic lateral sclerosis
VBA 8023 Progressive muscular atrophy
VBA 8005 Bulbar palsy
VBA, Veterans Benefits Administration.
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Table V
Best algorithm for determining true cases of ALS from administrative data. a
Neurologist review
ALS Not ALS Algorithm ALS Not ALS
• A visit for ALS in ≥ 1 year + death certificate b or Rx for 
riluzole c; OR
• No ALS visit e & no Rx for 
riluzole c; OR
ALS 1385 252
• A visit for ALS in ≥ 2 years + neurologist visit d; OR • A visit for ALS in 1 year & no 
neurologist visit d; OR
Not ALS 211 1474
• Age < 65, a visit for ALS in Medicare + neurologist visit; 
OR
• Age < 18 years; OR Sensitivity = 0.87
Specificity = 0.85
• A visit for ALS in ≥ 1 year + neurologist visit d and a visit 
for ALS in another database; OR




• A visit for ALS in ≥ 3 databases; OR • Death certificate only
• A visit for ALS in 1 year and ≥ 5 neurologist visits d
PPV, positive predictive value; NPV, negative predictive value.
a
National Databases include Veterans Health Administration, Veterans Benefits Administration, Medicare, and Medicaid.
b
Death certificate includes ICD-10 code G12.2 for motor neuron disease. Death certificates are not an independent database because there is not a 
specific code for ALS.
c
Riluzole is the only prescription medication specifically used to treat ALS.
d
In the same database.
e
One or more visits for a motor neuron disease other than ALS.
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